Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Platelet Targeted Therapeutics LLC operates in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action represents the entirety of the company's active engagement with the patent office. Such a focused portfolio suggests a very specific technical or commercial goal for the company's current intellectual property filings, likely centered on a key therapeutic platform.
The examination process is centralized, with 1 distinct examiner and a distinct art unit involved. This means that the company's patent applications are being reviewed by a single technical expert within a single administrative division. This structure reduces the complexity of the prosecution, as the applicant only needs to respond to the requirements of one specific examiner, facilitating a more consistent dialogue between the legal team and the patent office.
QIAN, CELINE X is the busiest examiner for this portfolio, holding the busiest examiner pending office action. As the only examiner currently assigned to the company's pending matters, the evaluation of QIAN, CELINE X is the sole factor in the current prosecution. The 1 pending office action is the only hurdle the company must overcome to advance its position in the Biotechnology & Pharmaceuticals field and secure its targeted therapeutic claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18366237 | PLATELET TARGETED TREATMENT | QIAN, CELINE X | 13d |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18366237 | PLATELET TARGETED TREATMENT | QIAN, CELINE X | 1637 | §112 | Final Rejection | 13d | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial